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TranscriptionPV) are small DNA viruses that contain a compact and non-redundant genome.
HPV, with the help of only few genes, can achieve a complete vegetative cycle speciﬁcally in the epidermal
and mucosal keratinocytes. Modiﬁcation of the host cell transcriptional regulation is one of the major ways to
regulate the viral production and maturation. The vegetative cycle of papillomaviruses is linked to terminal
differentiation of the epithelium and is dependent on the host cell regulatory networks for transcriptional
control. The mucosal high risk HPV16 and HPV18 types have been the main models to explore this
transcriptional regulation mainly because they are prevalent in cervical cancer as the best studied virally
induced cancers in human. In addition, the availability of cell lines, grown from cervical cancers containing
integrated HPV16 or 18, represent versatile in vitro models for transcription studies. We will describe here
some aspects of the transcriptional regulation that contribute to cell speciﬁcity, the basis of which is not yet
fully understood despite efforts of numerous groups during the past two decades. Another speciﬁcity of small
DNA viruses is the multifunctional characteristics of their regulatory proteins due to extreme genomic
constraint. We will describe the role played by the viral E2 proteins in the transcriptional repression of the
high risk HPV oncogenes and its implication in cervical cancer.
© 2008 Elsevier Inc. All rights reserved.Transcriptional regulation of the HPV early genes in
cervical cancer
A basic feature of HPV associated cancer cells is that part of the
viral genome is integrated in the host cell genome. Conserved
characteristics of this integration include tandem repeats from a
single to several hundreds copies, of the viral DNA at random locations
in the cellular genome. Usually only a segment of the viral genome is
integrated containing the regulatory region or “Long Control Region”
also called “LCR”, and part of the early region, including the E6 and E7
open reading frames encoding the two main oncogenes. These two
genes are transcribed in at least two messengers initiated at a unique
promoter contained within the viral regulatory region called P105 for
HPV18 and P97 for HPV16 and HPV31, located immediately upstream
of the E6 open reading frame. Another important aspect of this
integration is the disruption of the open reading frames of E1 and/or
E2 downstream to the E7 gene. Since E1 and E2 are the two proteins
involved in viral DNA replication, integration leads to disruption of
viral DNA replication. At the same time, and since E2 has been shown
to repress E6 and E7 transcription through repression of the viral early
promoter (Thierry and Yaniv, 1987), disruption of E2 results in
transcriptional activation of the E6 and E7 oncogenes in cervicall rights reserved.cancer. Consequently, transcription of E6 and E7 in cervical carcinoma
cells is positively controlled by cellular transcription factors rather
than by viral transcription factors.
Structure and function of the HPV early promoter
The early promoter was named after the genomic sequence with
numbering corresponding to the 5′ end of the E6 and E7 messenger
RNAwhich are nucleotide 105 for HPV18 and 97 for HPV16 and HPV31
for instance. These early messengers exhibit very short if any leader
sequences. For instance, in HPV18, nucleotide 105 coincideswith the A
of the ATG initiation codon of the E6 open reading frame (Thierry et al.
1987). As expected for RNA Polymerase II promoters, a consensus
TATA box is present in the viral promoter, upstream of the
transcription initiation site, that recruits the TFIID general transcrip-
tion factor. Upstream sequences of this TATA box contain a transcrip-
tional enhancer to which cellular transcription factors bind (Garcia-
Carranca et al., 1988; Gloss et al., 1987; Swift et al., 1987). Sequences of
these enhancers and the transcription factors involved are only partly
conserved among mucosal HPVs, although these viruses exhibit the
same host restriction. Among elements distinctively conserved in the
mucosal HPV genomes are the sequences and locations of the binding
sites for the viral E2 proteins. There are four of them distributed in the
regulatory regions at comparable locations upstream of the initiation
site, with two tandem repeated sites located 3 or 4 nucleotides
upstream of the TATA box. This unique distribution of the E2 binding
Fig. 1. Schematic representation of the HPV18 regulatory regionwith the binding sites for transcription factors represented. The four E2 binding sites are shown and their disposition
and spacing are conserved among mucosal HPV types as well as the TATA box binding the general transcription factor TFIID and the SP1 binding sites. The E1 binding site deﬁned the
origin of replication together with the adjacent E2 binding sites. The core enhancer sequence is shown containing AP1 which has been shown to be involved in regulation of several
other HPV types and HMGI/Yand nucleolinwhich are more speciﬁc for the HPV18 transcription, GRE (Gloss et al., 1987; Medina-Martinez et al., 1996), YY1 and C/EBP beta (Bauknecht
et al., 1992; Bauknecht et al., 1996) and NF1 (Chong et al., 1991) are also shown.
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whereas in other papillomaviruses their numbers and locations vary
(Sanchez et al. 2008) (Fig. 1). The exact role played by E2 in
transcriptional regulation in these various models is however not
yet fully understood. E2 has been demonstrated to be a transcriptional
activator of early genes in the bovine BPV1 and a repressor of early
genes in the human mucosal HPV (Spalholz et al., 1985; Thierry and
Yaniv, 1987).
The emerging picture of HPV early promoter transcription can
therefore be recapitulated by two points: ﬁrst, activation by an array of
cellular transcription factors binding to a regulatory region upstream
of an RNA Polymerase II promoter and second, repression by binding
of the viral E2 transcription factor to sites within the promoter itself.
Mechanisms involved in both of these regulatory pathways have been
extensively studied although several aspects remain unclear. For
instance, and this can be considered as one of the major ﬂaw in our
knowledge regarding HPV transcription, the keratinocyte speciﬁcity is
not yet fully understood. Indeed many transcription factors involved
in HPV transcription have been described over the years since the ﬁrst
depiction of the HPV 18 early promoter, more than 20 years ago in
1987, (Thierry et al., 1987) but none of them are cell speciﬁc, although
their combination may exhibit a certain level of speciﬁcity.
The cellular transcription factors
Among the main players involved in HPV transcription are the
ubiquitous transcription factors SP1 (Gloss and Bernard, 1990; Hoppe-
Seyler and Butz, 1992) and AP1 (Thierry et al., 1992). Both have been
found to play a critical role in mucosal HPV including high risk types
18, 16, 31, or low risks types 6 and 11 as their binding sites can be
found in the regulatory regions of the mucosal HPVs. SP1 is a
ubiquitous transcription factor which is involved in the transcriptional
regulation of as many as 30% of the cellular genes (Cawley et al., 2004).
Its GC rich binding site is generally found in the promoter regions,
close to the transcriptional initiation site but not in the enhancers, as
reviewed in Wierstra (2008). In the mucosal HPV genomes, SP1 is
found just upstream of the E2 binding sites, part of its binding
sequence overlapping with E2 binding. This speciﬁc arrangement,
together with the close proximity of the E2 binding sites to the TATA
box, (Fig. 1) is probably involved in transcriptional repression as the
binding of E2 resulted in steric hindrance which prevented the
formation of the transcriptional initiation complex by displacing TFIID
and Sp1.
In contrast, AP1 is frequently involved in enhancer function and is
constituted by heterodimers of Jun and Fos proteins belonging to two
different families of proto-oncogenes. AP1 are also quasi-ubiquitous
transcription factors whose activities are modulated through signal
transduction, thus providing a large range of regulatory potentialities.
Further levels of modulation of AP1 activities are mediated through
differential expression of the factors belonging to the two families in
different tissues and speciﬁc interaction with other transcription
factors, reviewed in Zenz and Wagner (2006) and Hess et al. (2004).Interaction of AP1 with other transcription factors can occur upon
cooperative binding to adjacent sites inducing speciﬁc and synergistic
transcriptional activation, for instance with the HMGI/Y factor, as
described for the HPV18 enhancer (Bouallaga et al., 2000). HMGI/Y is
an architectural transcription factor highly expressed in cancer and
more particularly in cervical carcinoma, thus inducing a strong
activation of the E6 and E7 transcription in these cells (Bouallaga et
al., 2000). Interestingly, E7 induces transcriptional activation of
HMGI/Y through E2F activation, as found in microarray analyses
(Thierry et al., 2004), thus indicating that an auto-activating loop may
allow ampliﬁcation of the E7 transcription in cervical carcinoma. The
AP1 and HMGI/Y binding sites are central to a three dimensional
structure called enhanceosome which is formed in the HPV18
regulatory region (Bouallaga et al., 2000) and was ﬁrst described in
1995 for two cellular genes, IFN beta (Falvo et al., 1995; Thanos and
Maniatis, 1995) and TCR alpha (Giese et al., 1995). It is not possible at
the moment to extend this concept to the other mucosal HPVs,
although AP1 binding sites have been found in all HPV regulatory
regions studied so far. Recruitment of the CBP/p300 histone acetylase
coactivator by the HPV18 enhanceosome has also been shown in
cervical carcinoma cells (Bouallaga et al., 2003) but nothing is known,
at the moment, regarding the putative role of these coactivators in
keratinocytes. The central function of the AP1 transcription factors in
keratinocyte differentiation and their involvement in the regulation of
several speciﬁc cellular genes such as involucrin, loricrin, cytokeratins
or integrins, highlighted their putative crucial function in this cell
type speciﬁc papillomavirus transcriptional control. In this respect,
the heterodimers modulating HPV18 expression mainly contain JunB
and Fra2 which are highly expressed in keratinocytes and are
modulators of their differentiation (Bouallaga et al., 2003; Mehic et
al., 2005).
HPV transcription exhibits stringent cell speciﬁcity in that the viral
regulatory region is not active in cell types other than keratinocytes or
cervical carcinoma cells (Fig. 2). As depicted above, AP1 plays a central
role in this speciﬁcity but it is not sufﬁcient to account for the full
control exerted on the HPV transcription. Other transcription factors
that have been found involved such as GRE, NF1, YY1, Oct-1, C/EBP,
reviewed in Hoppe-Seyler and Butz (1994) and O'Connoret al. (1995)
or nucleolin for the HPV18 transcription (Grinstein et al., 2002), are
not speciﬁc either and, although the hypothesis that cooperation of
multiple nonspeciﬁc factors could confer speciﬁcity has been
suggested, no conclusive experiments have been done so far to
sustain this hypothesis. Nucleolin is an interesting example of
interaction of a ubiquitous protein that might bring about speciﬁcity
for dividing cells, since it activates HPV18 transcription in a cell cycle-
dependent manner, which in turn might amplify the potential of E7 to
activate S-phase genes. It binds the HPV18 enhancer region to an Oct-1
binding site, around 30 nucleotides downstream of the AP1 binding
site, in the core enhanceosome and could therefore participate to its
structure and function in cervical carcinoma (Fig. 1).
The functional signiﬁcance of the transcription factors involved in
HPV transcriptional regulation needs to be re-examined in vivo by
Fig. 2. Representative CAT assays of the HPV18 early promoter activity in various cell
lines. In cervical carcinoma cells lines (HeLa and C33) in human (HaCaT) and mouse
(XB2) keratinocytes and in an epithelial cell line (SW13), the transcription of the CAT
reporter gene is high while in liver carcinoma (HepG2), embryonic transformed cells
(293), human ﬁbroblast (H5) breast adenocarcinoma (MCF7) and mouse ﬁbroblasts
(NIH3T3), no transcription can be detected. The schematic representation of the CAT
reporter plasmid is shown.
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tions, either in cervical carcinoma cells or in keratinocytes at
different stages of differentiation. Recent data indicated that C/EBP-
alpha and C/EBP-beta play a role (Wooldridge and Laimins, 2008)
among several other transcription factors which have also been
found to bind in vivo to the regulatory region of the episomal form of
HPV16 in keratinocytes (Carson and Khan, 2006). However, more
work needs to be done to elucidate the basis of transcriptional cell
speciﬁcity of mucosal HPV.Fig. 3. Schematic representation of the fragment of HPV18 genome integrated in the cellular
from the P105 promoter and the products of these genes negatively interfere with p53 and p
expressed in HeLa cells, the viral E2 transcription factor represses the E6 and E7 transcript
senescence.Transcriptional repression by the viral transcription factor E2
The full length E2 protein has originally been described as a
transactivator of the BPV1 early transcription (Spalholz et al., 1985)
while a shorter form, deleted of the amino terminal transactivation
domain, was described as a repressor (Lambert et al., 1987). The E2
transcription factor is a speciﬁc DNA binding homodimer harbouring a
classical modular structure in three distinct domains (Giri and Yaniv,
1988; Dostatni et al., 1988; McBride et al., 1989). Binding sites for E2
are present in multiple copies in various papillomavirus type
regulatory regions although, as mentioned earlier, only 4 copies are
found in the regulatory regions of mucosal HPVs (Sanchez et al., 2008)
(Fig. 1). The distances between the four binding sites are conserved, 1
or 2 nucleotides between BS#1 and BS#2, the most proximal binding
sites to the promoter, while 64 nucleotides were found between the
E2 BS#2 and BS#3 and about 320 nucleotides span the BS#3 and the
most distal BS#4. As for the proximity of the E2 BS to the TATA box, it is
also well conserved involving 3 nucleotides for the majority of the
mucosal HPV.We and others have shown that the three sites proximal
to the TATA box are involved in E2 transcriptional repression of the
early promoters, with a prominent role played by the two most
proximal sites to the TATA box, (Romanczuk et al., 1990; Thierry and
Howley, 1991; Demeret et al., 1997), while at the same time these sites
are used for efﬁcient viral DNA replication in concert with the E1 viral
helicase (Demeret et al., 1995). As already mentioned, binding of E2
represses transcription through steric hindrance of the interaction
with the transcriptional initiation factor TFIID at the proximal TATA
box. Mechanism of transcriptional repression by E2 binding was ﬁrst
demonstrated in vivo in transfected cells (Romanczuk et al., 1990;
Thierry and Howley, 1991) and in vitro in cell extract (Dostatni et al.,
1991), as well as more recently with puriﬁed transcription factors
(Hou et al., 2000), indicating that E2 binding to the HPV regulatory
region precludes binding of TBP to the adjacent site.genome as in the HeLa cervical carcinoma cells. (A) The E6 and E7 genes are transcribed
RB respectively, thus inducing cell cycle deregulation and cell transformation. (B) When
ion thereby inhibiting their effects on p53 and pRB and inducing cell cycle arrest and
378 MinireviewThe structure and function of E2 as transcription factors are
conserved among papillomaviruses although their roles signiﬁcantly
differ in regulating transcription. Speciﬁcally, HPV E2 proteins have
retained fully functional transactivation domains that can activate
transcription of reporter genes in heterologous expression constructs,
although the transcriptional unit(s) activated in the homologous viral
genomes, are unknown. Activation by E2 requires cooperation of at
least two E2 dimers bound to cognate sequences which could be
adjacent or distant. More recently, dimerization of the HPV16 E2
amino-terminal transactivation domain over large distances has been
shown to induce looping of the intervening sequences, thus providing
another potential mechanism for E2 transcriptional regulation
(Hernandez-Ramon et al., 2008).
Interestingly, transcriptional repression requires an intact DNA
binding domain but also involves a competent transactivation domain
(Goodwin et al., 1998; Nishimura et al., 2000). This need for an intact
transactivation domain to fully repress transcription is not understood
yet, although it has been suggested that it might recruit transcrip-
tional corepressors. Alternatively, the same recruited factor(s), such as
the chromatin component BRD4 for instance, important for segrega-
tion of the viral genome during mitosis (You et al., 2004), could
participate in transcriptional activation or repression, depending on
the chromatin context (Schweiger et al., 2007) (Wu et al., 2006).
Looping of the regulatory sequences through interaction of the E2
amino-terminal domains, could also be involved in the mechanism of
repression (Hernandez-Ramon et al., 2008).
In this respect, distinct E2 repressor has been described in the
HPV31 model, whose amino terminal domain is replaced by a fusion
with the short E8 open reading frame which acts as an active
repressive domain able to repress transcription as well as replication
by recruiting corepressors (Ammermann et al., 2008; Stubenrauch et
al., 2000). A comparable E2 repressor has also recently been described
in the HPV16 model raising the possibility that such repressors could
also regulate transcription during the normal viral cycle in mucosal
HPV infection (Lace et al., 2008).
The roles of E2 in the viral infection and transformation
As described above, E2 is a transcription factor which binds to
speciﬁc cognate sequences in the viral genome and is able to repress
transcription from the HPV early promoters. This repression of the
viral oncogenes is relieved after integration of part of the viral genome
into the cellular genome by disruption of the E2 open reading frame
(Fig. 3A). It is believed that this process therefore leads to high levels of
E6 and E7 transcription as normally observed in cervical carcinoma
cell lines. When E2 is re-expressed in cervical carcinoma, it represses
the endogenous viral transcription leading to cell cycle arrest,
apoptosis and senescence, thus establishing altogether the negative
impact of E2 on carcinogenic progression and the need for the viral
oncogenes to be continuously expressed to maintain cervical
carcinoma cell proliferation (Fig. 3B) (Desaintes et al., 1997; Goodwin
and DiMaio, 2000; Hwang et al., 1993). This E2-mediated repression of
E6 and E7 transcription leads to dramatic changes in the HeLa cells
transcriptome through modulations of the p53 and p63 as well as E2F
transcription factors (Thierry et al., 2004; Teissier et al., 2007; Wells et
al., 2003; Johung et al., 2007) (Fig. 3B).
These paradoxical requirements reﬂect a complex usage of the
viral E2 regulator which activates replication and at the same time
represses transcription by binding to the same sites. Furthermore, this
binding could repress or activate transcription through interaction
with similar, if not identical, cofactors. More recently, E2 has also been
shown to be able to shuttle from the nucleus, where it is known to
function in transcription and replication, to the cytoplasm where it
activates caspase 8, thus inducing apoptosis (Blachon et al., 2005;
Thierry and Demeret, 2008). In addition, E2 has also been shown to
modulate the cell cycle, independently of transcription and DNAreplication regulatory functions (Bellanger et al., 2005). These new
functions are not conserved among mucosal HPV types and appear
linked to the oncogenic potential of high risk viruses. We showed
further that high risk HPVs are able to modulate the cell cycle through
the E2 proteins which induce mitotic arrest by interfering with the
mitotic ubiquitin ligase APC (Bellanger et al., 2005). This leads to
genomic instability and could play a prominent role in the early stages
of viral infection to predispose infected cells to transformation.
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